Insider Selling: Beta Bionics (NASDAQ:BBNX) CFO Sells $83,378.88 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 4,896 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $17.03, for a total transaction of $83,378.88. Following the transaction, the chief financial officer owned 165,931 shares of the company’s stock, valued at approximately $2,825,804.93. The trade was a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The stock was sold at an average price of $17.05, for a total transaction of $87,023.20.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The stock was sold at an average price of $12.61, for a total transaction of $84,184.36.

Beta Bionics Stock Performance

Shares of NASDAQ:BBNX traded down $1.33 on Tuesday, hitting $15.67. 931,657 shares of the company were exchanged, compared to its average volume of 1,141,549. The company’s 50 day moving average price is $12.23 and its two-hundred day moving average price is $15.41. The firm has a market capitalization of $698.29 million, a price-to-earnings ratio of -10.38 and a beta of 3.40. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The business had revenue of $27.63 million during the quarter. Research analysts predict that Beta Bionics, Inc. will post -2.22 earnings per share for the current year.

Institutional Investors Weigh In On Beta Bionics

Several large investors have recently modified their holdings of BBNX. Summit Securities Group LLC bought a new position in shares of Beta Bionics during the 4th quarter worth approximately $52,000. Caitong International Asset Management Co. Ltd grew its position in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares during the period. EverSource Wealth Advisors LLC raised its stake in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares in the last quarter. Strs Ohio bought a new position in shares of Beta Bionics during the first quarter valued at $29,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after acquiring an additional 1,863 shares during the period.

Wall Street Analysts Forecast Growth

BBNX has been the topic of several recent research reports. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Truist Financial reduced their target price on Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. The Goldman Sachs Group decreased their price target on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Leerink Partners lowered their price target on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Finally, Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.